• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    How Is The Market Feeling About Imara?

    10/14/22 2:13:06 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IMRA alert in real time by email

    Imara's (NASDAQ:IMRA) short percent of float has fallen 13.5% since its last report. The company recently reported that it has 1.37 million shares sold short, which is 9.87% of all regular shares that are available for trading. Based on its trading volume, it would take traders 0.5 days to cover their short positions on average.

    Why Short Interest Matters

    Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.

    Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.

    See Also: List of the most shorted stocks

    Imara Short Interest Graph (3 Months)

    short_fig

    As you can see from the chart above the percentage of shares that are sold short for Imara has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.

    Comparing Imara's Short Interest Against Its Peers

    Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.

    According to Benzinga Pro, Imara's peer group average for short interest as a percentage of float is 2.68%, which means the company has more short interest than most of its peers.

    Did you know that increasing short interest can actually be bullish for a stock? This post by Benzinga Money explains how you can profit from it..

    This article was generated by Benzinga's automated content engine and was reviewed by an editor.

    Get the next $IMRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMRA

    DatePrice TargetRatingAnalyst
    1/6/2022$12.00 → $4.00Equal-Weight
    Morgan Stanley
    11/30/2021$10.00Buy
    HC Wainwright & Co.
    8/11/2021$33.00 → $12.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $IMRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    5am Partners Vi, Llc sold $12,292,500 worth of shares (825,000 units at $14.90) (SEC Form 4)

    4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

    2/16/24 4:15:31 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Phillips Andrew John

    4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

    2/15/24 9:04:08 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Patel Anish

    4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

    2/15/24 9:02:21 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, Jan. 22, 2026 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH.  Fund Ticker Distribution Per Share Distribution Rate 30-Day SEC Yield Return of Capital Ex-Date / Record Date Payment Date 1-Month Return 1-Year Return Since InceptionReturn Bitwise COIN Option Income Strategy ETF ICOI $0.50284 36.87 % 0.00 % 50.00 % 01/23/2026 01/27/2026 -4.93 % N/A -10.58 % Bitwise MARA Option Income Strategy ETF IMRA $0.20782 14

    1/22/26 4:21:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, Dec. 24, 2025 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH. Fund Ticker Distribution Per Share Distribution Rate 30-Day SEC Yield Return of Capital Ex-Date / Record Date Payment Date 1-Month Return 1-Year Return Since InceptionReturn Bitwise COIN Option Income Strategy ETF ICOI $2.24702 140.11 % 0.00 % 100.00 % 12/26/2025 12/30/2025 -2.82 % N/A -7.33 % Bitwise MARA Option Income Strategy ETF IMRA $1.41664 100.18 % 0.00 % 100.00 % 12/26/2025 12/30/2025 -9.45 % N/A -35.18 % Bitwise MSTR Option Income Strategy ETF IMST $1.30

    12/24/25 1:12:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, Nov. 26, 2025 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH. Fund Ticker Distribution Per Share Distribution Rate 30-Day SEC Yield Return of Capital Ex-Date / Record Date PaymentDate 1-Month Return 1-Year Return Since InceptionReturn Bitwise COIN Option Income Strategy ETF ICOI $2.59493 140.33 % 0.00 % 100.00 % 11/28/2025 12/2/2025 -27.20 % N/A -5.10 % Bitwise MARA Option Income Strategy ETF IMRA $1.69441 100.07 % 0.00 % 100.00 % 11/28/2025 12/2/2025 -40.17 % N/A -28.64 % Bitwise MSTR Option Income Strategy ETF IMST $1.503

    11/26/25 4:30:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley reiterated coverage on Imara with a new price target

    Morgan Stanley reiterated coverage of Imara with a rating of Equal-Weight and set a new price target of $4.00 from $12.00 previously

    1/6/22 10:34:33 AM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HC Wainwright & Co. initiated coverage on Imara with a new price target

    HC Wainwright & Co. initiated coverage of Imara with a rating of Buy and set a new price target of $10.00

    11/30/21 7:23:31 AM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Imara downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Imara from Overweight to Equal-Weight and set a new price target of $12.00 from $33.00 previously

    8/11/21 6:17:27 AM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMRA
    SEC Filings

    View All

    SEC Form 144 filed by IMARA Inc.

    144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

    2/15/24 5:04:57 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by IMARA Inc.

    144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

    12/20/23 6:06:54 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by IMARA Inc.

    144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

    12/19/23 5:27:50 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMRA
    Financials

    Live finance-specific insights

    View All

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, Jan. 22, 2026 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH.  Fund Ticker Distribution Per Share Distribution Rate 30-Day SEC Yield Return of Capital Ex-Date / Record Date Payment Date 1-Month Return 1-Year Return Since InceptionReturn Bitwise COIN Option Income Strategy ETF ICOI $0.50284 36.87 % 0.00 % 50.00 % 01/23/2026 01/27/2026 -4.93 % N/A -10.58 % Bitwise MARA Option Income Strategy ETF IMRA $0.20782 14

    1/22/26 4:21:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, Dec. 24, 2025 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH. Fund Ticker Distribution Per Share Distribution Rate 30-Day SEC Yield Return of Capital Ex-Date / Record Date Payment Date 1-Month Return 1-Year Return Since InceptionReturn Bitwise COIN Option Income Strategy ETF ICOI $2.24702 140.11 % 0.00 % 100.00 % 12/26/2025 12/30/2025 -2.82 % N/A -7.33 % Bitwise MARA Option Income Strategy ETF IMRA $1.41664 100.18 % 0.00 % 100.00 % 12/26/2025 12/30/2025 -9.45 % N/A -35.18 % Bitwise MSTR Option Income Strategy ETF IMST $1.30

    12/24/25 1:12:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, Nov. 26, 2025 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH. Fund Ticker Distribution Per Share Distribution Rate 30-Day SEC Yield Return of Capital Ex-Date / Record Date PaymentDate 1-Month Return 1-Year Return Since InceptionReturn Bitwise COIN Option Income Strategy ETF ICOI $2.59493 140.33 % 0.00 % 100.00 % 11/28/2025 12/2/2025 -27.20 % N/A -5.10 % Bitwise MARA Option Income Strategy ETF IMRA $1.69441 100.07 % 0.00 % 100.00 % 11/28/2025 12/2/2025 -40.17 % N/A -28.64 % Bitwise MSTR Option Income Strategy ETF IMST $1.503

    11/26/25 4:30:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMRA
    Leadership Updates

    Live Leadership Updates

    View All

    Imara to Report Data Demonstrating the Potential of Tovinontrine (IMR-687) for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)

    Preclinical data from three different mouse models of HFpEF to be presented at American Heart Association (AHA) Scientific Sessions HFpEF development to be led by cardiologist Toni Bransford, M.D., FACC, FASE Imara's new Vice President of Clinical Development BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, announced data today in three preclinical mouse models of heart failure with preserved ejection fraction (HFpEF) treated with tovinontrine (IMR-687). Sele

    11/8/21 7:00:00 AM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Imara Announces Appointment of Laura A. Williams, M.D., MPH to Board of Directors

    BOSTON, June 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the election of Laura A. Williams, M.D., MPH to its Board of Directors. Dr. Williams brings 25 years of early-to-late-stage drug development experience across multiple therapeutic areas, as well as expertise in patient advocacy to Imara. "We're thrilled to welcome Dr. Williams to our Board," said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara. "In addition to her significant experience leading clinical

    6/30/21 7:00:00 AM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Imara Announces the Appointment of Kenneth Attie, M.D. as Chief Medical Officer

    BOSTON, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the appointment of Kenneth Attie, M.D. as Senior Vice President and Chief Medical Officer. Dr. Attie joins Imara with over 30 years of experience within academia and the biopharmaceutical industry, most recently at Acceleron Pharma, Inc. where he led global clinical development efforts that led to the recent FDA and EMA approvals of a new treatment for patients with rare anemias, including beta-thalassemia.  “We are exc

    1/20/21 7:00:00 AM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by IMARA Inc. (Amendment)

    SC 13D/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

    2/16/24 4:15:28 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by IMARA Inc. (Amendment)

    SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

    2/14/24 8:53:21 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by IMARA Inc. (Amendment)

    SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

    2/14/24 4:58:16 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care